130 related articles for article (PubMed ID: 20005259)
1. Tribbles-1 and -2 are tumour suppressors, down-regulated in human acute myeloid leukaemia.
Gilby DC; Sung HY; Winship PR; Goodeve AC; Reilly JT; Kiss-Toth E
Immunol Lett; 2010 May; 130(1-2):115-24. PubMed ID: 20005259
[TBL] [Abstract][Full Text] [Related]
2. Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interaction.
Rangatia J; Vangala RK; Singh SM; Peer Zada AA; Elsässer A; Kohlmann A; Haferlach T; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Jul; 22(30):4760-4. PubMed ID: 12879022
[TBL] [Abstract][Full Text] [Related]
3. The role of Trib1 in myeloid leukaemogenesis and differentiation.
Nakamura T
Biochem Soc Trans; 2015 Oct; 43(5):1104-7. PubMed ID: 26517931
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation.
Rishi L; Hannon M; Salomè M; Hasemann M; Frank AK; Campos J; Timoney J; O'Connor C; Cahill MR; Porse B; Keeshan K
Blood; 2014 Apr; 123(15):2389-400. PubMed ID: 24516045
[TBL] [Abstract][Full Text] [Related]
5. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia.
Keeshan K; He Y; Wouters BJ; Shestova O; Xu L; Sai H; Rodriguez CG; Maillard I; Tobias JW; Valk P; Carroll M; Aster JC; Delwel R; Pear WS
Cancer Cell; 2006 Nov; 10(5):401-11. PubMed ID: 17097562
[TBL] [Abstract][Full Text] [Related]
6. Tribbles breaking bad: TRIB2 suppresses FOXO and acts as an oncogenic protein in melanoma.
Link W
Biochem Soc Trans; 2015 Oct; 43(5):1085-8. PubMed ID: 26517928
[TBL] [Abstract][Full Text] [Related]
7. Differential ability of Tribbles family members to promote degradation of C/EBPalpha and induce acute myelogenous leukemia.
Dedhia PH; Keeshan K; Uljon S; Xu L; Vega ME; Shestova O; Zaks-Zilberman M; Romany C; Blacklow SC; Pear WS
Blood; 2010 Aug; 116(8):1321-8. PubMed ID: 20410507
[TBL] [Abstract][Full Text] [Related]
8. Balance of NF-kappaB and p38 MAPK is a determinant of radiosensitivity of the AML-2 and its doxorubicin-resistant cell lines.
Choi CH; Xu H; Bark H; Lee TB; Yun J; Kang SI; Oh YK
Leuk Res; 2007 Sep; 31(9):1267-76. PubMed ID: 17218010
[TBL] [Abstract][Full Text] [Related]
9. KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells.
Nakamura S; Okinaka K; Hirano I; Ono T; Sugimoto Y; Shigeno K; Fujisawa S; Shinjo K; Ohnishi K
Leuk Res; 2008 Sep; 32(9):1358-65. PubMed ID: 18384876
[TBL] [Abstract][Full Text] [Related]
10. CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
Paz-Priel I; Cai DH; Wang D; Kowalski J; Blackford A; Liu H; Heckman CA; Gombart AF; Koeffler HP; Boxer LM; Friedman AD
Mol Cancer Res; 2005 Oct; 3(10):585-96. PubMed ID: 16254192
[TBL] [Abstract][Full Text] [Related]
11. Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.
Yi S; Wen L; He J; Wang Y; Zhao F; Zhao J; Zhao Z; Cui G; Chen Y
Ann Hematol; 2015 Feb; 94(2):201-10. PubMed ID: 25242579
[TBL] [Abstract][Full Text] [Related]
12. Erythroid differentiation-associated gene interacts with NPM1 (nucleophosmin/B23) and increases its protein stability, resisting cell apoptosis.
Zhang MJ; Ding YL; Xu CW; Yang Y; Lian WX; Zhan YQ; Li W; Xu WX; Yu M; Ge CH; Ning HM; Li CY; Yang XM
FEBS J; 2012 Aug; 279(16):2848-62. PubMed ID: 22712502
[TBL] [Abstract][Full Text] [Related]
13. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
Cristóbal I; Garcia-Orti L; Cirauqui C; Alonso MM; Calasanz MJ; Odero MD
Leukemia; 2011 Apr; 25(4):606-14. PubMed ID: 21233840
[TBL] [Abstract][Full Text] [Related]
14. LDL uptake by monocytes in response to inflammation is MAPK dependent but independent of tribbles protein expression.
Eder K; Guan H; Sung HY; Francis SE; Crossman DC; Kiss-Toth E
Immunol Lett; 2008 Mar; 116(2):178-83. PubMed ID: 18308403
[TBL] [Abstract][Full Text] [Related]
15. Regulation of expression and signalling modulator function of mammalian tribbles is cell-type specific.
Sung HY; Francis SE; Crossman DC; Kiss-Toth E
Immunol Lett; 2006 Apr; 104(1-2):171-7. PubMed ID: 16364454
[TBL] [Abstract][Full Text] [Related]
16. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
[TBL] [Abstract][Full Text] [Related]
18. HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun.
Schepers H; Geugien M; van der Toorn M; Bryantsev AL; Kampinga HH; Eggen BJ; Vellenga E
Exp Hematol; 2005 Jun; 33(6):660-70. PubMed ID: 15911090
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.
Alachkar H; Mutonga MB; Metzeler KH; Fulton N; Malnassy G; Herold T; Spiekermann K; Bohlander SK; Hiddemann W; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2014 Dec; 5(23):12371-82. PubMed ID: 25365263
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals.
Hu ZB; Yang GS; Li M; Miyamoto N; Minden MD; McCulloch EA
Leukemia; 1995 May; 9(5):789-98. PubMed ID: 7769841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
